We studied anti-b2-glycoprotein I antibodies (ab2GPI) in autoimmune disease patients to evaluate their relationship to clinical findings. Seventy-nine systemic lupus erythematosus (SLE) patients [44 with antiphospholipid antibodies (aPL)], 21 with primary antiphospholipid syndrome (APS), eight asymptomatic individuals with aPL and 60 controls were studied. Sixteen SLE patients (14 with aPL and two without aPL) and six with primary APS had ab2GPI. A significant relationship was found between ab2GPI and aPL (P Q 0.01). In SLE, a significant correlation was found between previous thrombosis or thrombocytopenia and ab2GPI or ab2GPI + aPL, but not between fetal losses and ab2GPI. These data suggest that ab2GPI may be useful in the study of APS.
A antibodies (aPL) are frequently detected in patients with autoimmune diseases or other conditions [1] . In autoimmune disorders, aPL [anticardiolipin antibodies (aCL) and lupus anticoagulant (LA)] are associated with thrombosis, fetal losses and thrombocytopenia constituting the antiphospholipid syndrome (APS) [2] . However, in infectious diseases, aPL are usually not associated with clinical manifestations [1, 2] . The reasons why only some patients with aPL develop APS have not been elucidated. aCL bind cardiolipin in the presence of their cofactor b 2 -glycoprotein I (b 2 GPI) [3] [4] [5] [6] . b 2 GPI inhibits the coagulation cascade and platelet function [7, 8] , and binds to negatively charged phospholipids [5] [6] . Whether aCL recognize a cryptic epitope on b 2 GPI or the epitope consists of both b 2 GPI and cardiolipin is still open to discussion [4, [9] [10] [11] . The discovery of antibodies against b 2 GPI (ab 2 GPI) in systemic lupus erythematosus (SLE) and primary APS patients [12] [13] [14] [15] [16] [17] [18] suggests that b 2 GPI may play a role in the pathogenesis of APS. We determined ab 2 GPI in a series of patients with autoimmune diseases to evaluate their relationship to clinical manifestations.
METHODS

Patients
We studied 108 patients: (i) 79 with SLE [19] : including 44 with aPL (40 female/4 male, mean age 41.3 2 15.7 yr) and 35 without aPL (32 female/3 male, mean age 37.8 2 13.2 yr); (ii) 21 with primary APS [2] (18 female/3 male, mean age 29.9 2 5.4 yr); (iii) eight asymptomatic individuals with aPL (eight female, mean age 32.0 2 2.7 yr). Twenty-one patients (14 with SLE and seven with primary APS) had a history of thrombosis confirmed by venogram or arteriography. Twenty-five women had fetal losses (nine with SLE and 16 with primary APS) and 32 patients had a history of thrombocytopenia (29 with SLE and three with primary APS). Controls were 60 healthy volunteers (31 female/29 male, mean age 35.7 2 19.4 yr) without autoimmune diseases, bleeding disorders, thrombosis or pregnancy losses.
Samples were drawn in trisodium citrate and in non-anticoagulated tubes (Becton Dickinson, Rutherford, NJ, USA). Platelet-free plasma was obtained by double centrifugation [first at 2000 g (10 min, 22°C) and then at 5000 g (10 min, 4°C)], frozen, and stored at −70°C.
Detection of ab 2 GPI by ELISA
Microtitre plates Maxisorp (Nunc, Roskilde, Denmark) were coated (16 h, 4°C) with 100 ml of 25 mg/ml human b 2 GPI (Behringwerke, Marburg, Germany) in 16 mmol/l Na 2 CO 3 /34 mmol/l NaHCO 3 (pH 9.6). This coating concentration showed the best differentiation between specific binding and background. After washing with phosphate-buffered saline + 0.1% Tween 20 (Merk, Munchen, Germany) (PBS-Tween), coated plates were blocked (1 h, 22°C) with 300 ml of 5% bovine serum albumin (BSA) (Sigma, St Louis, MO, USA) in PBS-Tween. The wells were then incubated Tests were also performed in mixtures with control plasmas or phospholipids [22] .
Statistical analysis
Results are shown as mean 2 .. Associations were assessed by x 2 test with Yates' correction. Sensitivity, specificity and odds ratios (OR) were determined by contingency tables. Intra-and interassay coefficients of variation were calculated as recommended [23] .
RESULTS
Results of ab 2 GPI are shown in Table I . Sixteen SLE patients (20.2%) and six primary APS (28.6%), but no asymptomatic individuals with aPL or controls, had ab 2 GPI. Patients with aPL had a significantly higher prevalence of ab 2 GPI than those without aPL (P Q 0.01). This relationship was also found in the SLE group (P Q 0.01). Only two patients (5.7%) without aPL had ab 2 GPI. A relationship was found between aCL and ab 2 GPI in both IgG and IgM isotypes (P Q 0.01). However, no increased presence of ab 2 GPI was observed in patients with LA but not aCL.
In SLE, thrombotic episodes were related to ab 2 GPI (P Q 0.01) in both IgG and IgM ab 2 GPI isotypes, and to ab 2 GPI + aPL (P Q 0.01) (Table II) . Specificity for thrombosis was higher using ab 2 GPI than aPL. A combination of both aPL and ab 2 GPI showed the best OR for thrombosis. No relationship was found between thrombosis and ab 2 GPI in patients with primary APS (2/6 with ab 2 GPI vs 5/15 without ab 2 GPI).
Thrombocytopenia was related to ab 2 GPI (P Q 0.01) and to ab 2 GPI + aPL (P Q 0.01) in SLE (Table II) , but not in primary APS patients (2/6 vs 1/15, NS). IgM ab 2 GPI (P Q 0.05), but not IgG, was related to thrombocytopenia. Specificity for thrombocytopenia was higher using ab 2 GPI. Positivity in both aPL and ab 2 GPI showed the best OR.
No relationship was observed between ab 2 GPI and fetal losses either in SLE (Table II) or in primary APS (5/5 with ab 2 GPI vs 11/13 without ab 2 GPI). DISCUSSION ab 2 GPI have been found in APS with prevalence ranging from 0 to 90% [4, 9-10, 12-18, 24] . In our series, ab 2 GPI prevalence was 32% in SLE aPL-positive patients, 6% in SLE aPL-negative, and 29% in H 2 SO 4 and optical density measured at 492 nm (OD 492 ). Intra-and interasssay coefficients of variation were 7.0 and 8.1 for IgG, and 11.7 and 12.1 for IgM. In each assay, two IgG and two IgM ab 2 GPI sera and 10 negative sera were used as controls. OD 492 values higher than 3 .. above the mean of negative controls were considered positive. Using b 2 GPI-coated plates, mean OD 492 of 10 positive and 10 negative sera were, respectively, 1.042 2 0.284 and 0.106 2 0.096 for IgG, and 1.212 2 0.342 and 0.130 2 0.107 for IgM; and were 0.070 2 0.032 and 0.084 2 0.041 for IgG, and 0.096 2 0.073 and 0.101 2 0.090 for IgM, respectively, using no antigen-coated plates.
Detection of aCL
aCL were measured using an ELISA [20] . Results were expressed in IgG and IgM units [21] , and reported as negative (Q15 units), low positive (16-25 units), moderate positive (26-40 units) and high positive (q40 units).
Detection of LA
LA was detected using prothrombin-activated partial thromboplastin time, diluted Russell's viper venom time and tissue thromboplastin inhibition test. primary APS. Differences in patient populations and in laboratory methodology, mainly b 2 GPI concentration and the use of irradiated plates, may be the reason for these discrepancies [24] . It has been suggested that high coating b 2 GPI concentrations might magnify the effect of phospholipid contamination [24] . However, ab 2 GPI have been found using low concentrations of b 2 GPI [15, 16] . ab 2 GPI have been determined in APS patients using irradiated [13] [14] 18] and non-irradiated [12, [15] [16] [17] polystyrene plates. Although a more specific binding has been suggested in irradiated plates [13] , it seems that irradiation should work by increasing the density of antigen sites [25] . In our assay, we obtained a good differentiation between specific binding and background using irradiated plates. Despite the association between aPL and ab 2 GPI [12] [13] [14] [15] [16] [17] [18] , two aPL-negative patients had ab 2 GPI and 70% patients with aPL had no ab 2 GPI. These results, and the differences in aCL and ab 2 GPI isotype distribution, indirectly suggest that aCL and ab 2 GPI conform to two populations of antibodies that are related but not equivalents.
We observed an association between ab 2 GPI and thrombosis, as reported by others [12] [13] [14] [16] [17] [18] , and also between ab 2 GPI and thrombocytopenia, which has been less commonly described [14, 17, 18] . It is interesting that positivity in both aPL and ab 2 GPI showed the best specificity and OR for thrombosis and for thrombocytopenia. Despite the relationship found between ab 2 GPI and recurrent fetal losses [14] , we and others [13, 17] have not confirmed this association.
The effect of ab 2 GPI in the pathophysiology of thrombosis or thrombocytopenia is unknown. It may be attributed to b 2 GPI properties inhibiting the intrinsic coagulation pathway [7] and ADP-induced platelet aggregation [8] . ab 2 GPI could participate in the thrombogenesis through the inhibition of these anticoagulant properties.
In conclusion, it seems that both aPL and ab 2 GPI are useful in the APS, but the higher specificity for clinical manifestations of ab 2 GPI determination supports their use after aPL determination. A Supported by Spanish grants FIS94/0323, FIS95/ 0250 and FIS96/0580.
